FEATURE ARTICLES
How API manufacturers can assess and mitigate organic impurities and nitrosamines using risk-based strategies aligned with global regulatory expectations.
- CDMO Selection: Start With The Relationship, Not The RFP
- Why FAT Should Confirm Alignment, Not Reveal Its Absence
- What Reliance, Annex 1, And AI Mean For The Future Of GMP
- Applying Contamination Control By Design: A Practical Guide For CDMOs
- Navigating Rough Pharma Seas With Collaboration
- Field Notes: Freeing Process Data For Automation At Kivi Bio AI Summit
- Rethinking CQV In A Digital, Agile Manufacturing Landscape
PHARMA ONLINE WHITE PAPERS
-
Manufacturing Of Cytotoxic And Non-Cytotoxic Drugs In A Multiproduct Facility
The experience and expertise of the CMO is crucial to avoid the risk of cross-contamination of the drug product, as failures or weaknesses in this process can pose risk to the end-user.
-
IP Considerations In Drug Development For Biotech Companies4/20/2026
Integrate a strategic intellectual property approach early in drug development to streamline research, uncover opportunities, and maximize the return on your investment.
-
Exploring Agentic AI In GMP Operations8/12/2025
Discover how agentic AI is poised to transform Enterprise Asset Management in regulated industries to enhance compliance, reduce downtime, and bridge fragmented systems for resilient operations.
-
History Of Peptides In Medicine: From Early Chemistry To The GLP-1 Era4/21/2026
Peptide therapeutics from early chemical breakthroughs to today’s metabolic drugs, highlighting scientific, clinical, and manufacturing advances shaping modern drug development.
-
Transitioning Your Product From Phase 1 To Phase 2 Clinical Studies12/13/2024
Strategic partnerships can streamline your transition from Phase 1 to Phase 2 clinical studies, ensuring optimized dosage forms, seamless scale-up, and alignment with patient and study requirements.
-
White Paper: Characterization Of Spray Dried Biologics5/7/2025
Discover how spray drying can transform the formulation of complex biologics by improving stability, delivery, and functionality, with insights into the critical techniques and strategies needed for successful development.
PHARMA ONLINE APP NOTES & CASE STUDIES
- Improving API Solubility With Mesoporous Silica
- Ensuring Consistent Quality In Pharmaceutical Water For Injection (WFI) Systems Application Note
- Predicting Performance Of Lotions Through Rheological Characterization
- Delivering Value Across Sites With Unified Quality Operations
- Assessing Viability And Real-Time Apoptosis/Necrosis
NEWSLETTER ARCHIVE
- 06.04.26 -- Closing The MES Value Gap: Why Technology Isn't The Problem
- 06.04.26 -- STREAM Edition: Interventions And Automation
- 06.02.26 -- Navigating Combination Product Development For Novel Biologics
- 06.02.26 -- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
- 06.01.26 -- Advancing Pharma Packaging, Inspection And Drug Delivery
INDUSTRY NEWS
-
ISPE Announces 2026 FOYA Winners
These awards recognize pharmaceutical and biopharmaceutical manufacturing projects that demonstrate excellence across innovation, operations, supply chain, Pharma 4.0, and social impact.
-
Høeg In, Pazdur Out At The FDA
What an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
-
9 Drugs Granted Fast Track By FDA's Voucher Program
With targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
Leaders In The Excipient Market: Region And Type
Though North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
Pfizer Strengthens Obesity Foothold With Metsera Acquisition
After discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Veranova Appoints Dr. Bob Huang Vice President And General Manager Of West Deptford Site6/3/2026
Veranova today announced the appointment of Dr. Bob Huang as Vice President and General Manager for its West Deptford, New Jersey facility. He will lead site operations, advance strategic growth initiatives, and strengthen manufacturing excellence and customer delivery.